在本研究中，我們在飲用水中添加乙二醇，藉由增加攝取此種草酸 前驅物，我們已經成功地誘發大鼠腎臟內的草酸鈣結晶沉積，並進而形 成腎結石。而本實驗過程中並沒有大鼠因此死亡，表示使用此模式可以 有效地達成目的。
實驗後的生化尿液數據變化，可能與五苓散的作用有關，尚待進一 步證實。研究期間我們自行研發的圖片瀏覽程式，的確可以有效地簡化 統計分析工作。
灌食五苓散並飲用添加乙二醇水的大鼠，其體重增加情形與對照組 無異，推測五苓散可能是藉由減少草酸鈣結晶，因而減輕腎臟損傷，讓 大鼠能夠維持正常成長。
Alcohol dehydrogenase具有分解乙二醇的作用，本研究在正常大鼠 腎組織中，發現此酵素的蹤跡，意味著腎臟也具有分解乙二醇的功能。
我們在飲用乙二醇水的大鼠腎臟內，發現酵素AGT2的存在，代表著中 毒大鼠正積極加速glyoxylate此毒素的轉換清除工作。
經由腎切片結晶沉澱嚴重度評分結果，我們發現餵食五苓散的大鼠 腎結晶程度，明顯的低於只餵食安慰劑的大鼠。因此，我們證實灌食五 苓散可以顯著有效地減輕結晶的嚴重程度，五苓散在動物體內可以有效 的抑制草酸鈣腎結石。
而且，餵食五苓散可以有效的減少大鼠腎結石的發生率。同時，與 安慰劑組對比之下，餵食五苓散的兩組大鼠其罹患腎結石的相對危險性 也比較低。
因此我們可以歸納結論，五苓散的確是一個預防腎結石的有效方 劑。雖然，五苓散的抑石機轉尚未明瞭，推測尿液中的蛋白質應該扮演 著重要角色，期待日後能進一步深入研究。
參考文獻：
1. 中央健康保險局:
http://210.69.214.131/webdata/AttachFiles/Attach_8327_2_94 年 CCS 統計.pdf. 2005.
2. Ho SZ, Kuo HC: Pathogenesis and epidemiology of urolithiasis. Tzu Chi Med J 2002, 14:337-346.
3. Lee YH, Huang WC, TSAI JY: Epidemiological studies on the prevalence of upper urinary calculi in Taiwan. Urol Int 2002, 68:172-177.
4. Menon M, Resnick M: Urinary lithiasis: etiology , diagnosis, and medical management. In: Campbell's Urology Edited by Walsh PC RA, Vaughan ED, Jr., Wein AJ 8th edn. Philadelphia: WB Saunders;
2002: 3229-3270.
5. Kim HH, Jo MK, Kwak C, Park SK, Yoo KY, Kang D, Lee C:
Prevalence and epidemiologic characteristics of urolithiasis in Seoul, Korea. Urology 2002, 59:517-521.
6. Yoshida O, Terai A, Ohkawa T, Okada Y: National trend of the
incidence of urolithiasis in Japan from 1965 to 1995. Kidney Int 1999, 56:1899-1904.
7. Takasaki E, Shimano E, Nagata M: [Sizes of upper urinary tract calculi and methods to remove these calculi (author's transl)]. Nippon Hinyokika Gakkai Zasshi 1976, 67:1025-1032.
8. Matsushita T: [Statistical observation of urolithiasis at the Hokkaido University Hospital (1959-1975) (author's transl)]. Hokkaido Igaku Zasshi 1978, 53:322-327.
9. Wikipedia:
http://en.wikipedia.org/wiki/Taiwan#Environment_and_population.
2007.
10. Wikipedia:
http://en.wikipedia.org/wiki/List_of_countries_by_population_density
#_note-cia. 2007.
11. 2005 年全民健康保險統計動向:醫療設備之國際比較 http://www.doh.gov.tw/statistic/data/全民健康保險統計動向 /2005/2005.htm
12. Chen YC, Ho CY, Chen LD, Hsu SF, Chen WC: Wu-Ling-San formula inhibits the crystallization of calcium oxalate in vitro. Am J Chin Med 2007, 35:533-541.
13. 陳育正: 五苓散對於體外草酸鈣結石模型和大鼠草酸鈣結石模型 的抑制作用. 碩士論文. 臺中, 台灣: 中國醫藥大學; 2006.
14. 維基百科，自由的百科全書: 五苓散
A3. In.; 2009.
15. Cao Z, Liu J, Zhou S: Effect of alisma orientalis extract on renal stone formation and the expression of inter-alpha-trypsin inhibitor in rat urolithiasis model. Chin J Exp Surg 2004, 21(3):295-297.
16. Liu Q, Sato S, Kishikawa T, Matsuzaki H, Yamanaka N: Effectiveness of a traditional Chinese medicine, Wulingsan, in suppressing the
development of nephrocalcinosis induced by a high phosphorus diet in young rats. Med Electron Microsc 2001, 34:103-114.
17. Hattori T, Hayashi K, Nagao T: Studies on antinephritic effects of plant components(3): effect of pachyman, a main component of Poria cocos Wolf on original-type anti-GBM nephritis in rats and its mechanisms. Jpn J Pharmacol 1992, 59(1):89-96.
18. Bensky D, Barolet R: Chinese herbal medicine: Formulas & Strategies.
Seatle, Washington: Eastland; 1990.
19. Lee Y, Huang W, Chiang H: Determinant role of testosterone in the pathogenesis of urolithiasis in rats. J Urol 1992, 147:1134-1138.
20. Nelde H, Bichler K, Strohmaier W: Nephrocalcinosis in the Kidney of the Rat on Atherogenic Diet and the Efffect of Calcium Antagonists (Nifedipine). In: Nephrocalcinosis calcium antagonists and kidney.
Edited by Bichler K, Strohmaier W. Berlin: Pringer-Verlag 1988:
113-125.
21. Lee Y, Chang L, Chen M: Characterization of ethylene glycol induced urolithiasis modle in rats. J Urol ROC 1991, 2:518-524.
22. 桃胶的功效介绍
25. Atmani F, Khan SR: Effects of an extract from herniaria hirsuta on calcium oxalate crystallization in vitro. BJU International 2000, 85:621-625.
26. Joshi VS, Parekh BB, Joshi MJ, Vaidya AD: Inhibition of the growth of urinary calcium hydrogen phosphate dihydrate crystals with
aqueous extracts of Tribulus terrestris and Bergenia ligulata. Urol Res 2005, 33:80-86.
27. Das I, Gupta S, Ansari S, Pandey V, Rastogi R: In vitro inhibition and dissolution of calcium oxalate by edible plant Trianthema monogyna and pulse Macrotyloma uniflorum extracts. Journal of Crystal Growth 2005, 273:546-554.
28. Nishiura JL, Campos AH, Boim MA, Heilberg IP, Schor N:
Phyllanthus niruri normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. Urol Res 2004, 32:362-366.
29. Suzuki K, Kawamura K, Tsugawa R: Formation and growth inhibition of calcium oxalate crystals by takusha(Alismatis rhizoma). Scanning Microscopy 1999, 13:183-189.
30. Utsunomiya M, Koide T, Yamaguchi S, Yoshioka T, Sonoda T, Sugiyama K: The effect of kanpou medicine on the growth and
aggregation of calcium oxalate crystals in vitro. Hinyokika Kiyo 1991, 37:1097-1101.
31. Koide T, Yamaguchi S, Utsunomiya M, Yoshioka T, Sugiyama K: The inhibitory effect of kampou extracts on in vitro calcium oxalate
crystallization an in vivo stone formation in an animal model. Int J Urol 1995, 2(2):81-86.
32. Uribarri J, Oh MS, Carroll HJ: The first kidney stone. Ann Intern Med 1989, 111:1006-1009.
33. Curhan GC, Willett WC, Rimm EB, Stampfer MJ: A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993, 328:833-838.
34. 李瀛輝, 張心湜, 陳明村, 黃榮慶: 台灣南部地區尿路結石流行病 學之研究. 中華民國泌尿科醫學會雜誌 1994, 5:1-7.
35. Fan J, Chandhoke PS, Grampsas SA: Role of sex hormones in
experimental calcium oxalate nephrolithiasis. J Am Soc Nephrol 1999, 10 Suppl 14:S376-380.
36. Fan J, Glass MA, Chandhoke PS: Effect of castration and finasteride on urinary oxalate excretion in male rats. Urol Res 1998, 26:71-75.
37. Lee YH, Huang WC, Huang JK, Chang LS: Testosterone enhances whereas estrogen inhibits calcium oxalate stone formation in ethylene glycol treated rats. J Urol 1996, 156:502-505.
38. Prince CL, Scardino PL, Wolan CT: The effect of temperature, humidity and dehydration on the formation of renal calculi. J Urol 1956, 75:209-215.
39. Bateson EM: Renal tract calculi and climate. Med J Aust 1973, 2:111-113.
40. Sallis JD, Parry NF, Meehan JD, Kamperman H, Anderson ME:
Controlling influence of phosphocitrate in vitro and in vivo on
calcium oxalate crystal formation and growth. Scanning Microsc 1995, 9:127-135; discussion 135-126.
41. Wilson DM: Clinical and laboratory approaches for evaluation of nephrolithiasis. J Urol 1989, 141:770-774.
42. Daudon M, Donsimoni R, Hennequin C, Fellahi S, Le Moel G, Paris M, Troupel S, Lacour B: Sex- and age-related composition of 10 617
43. 何淑貞, 郭漢崇: 尿路結石之成因與流行病學. 慈濟醫學雜誌 2002, 14:337-346.
44. Silverman DE, Stamey TA: Management of infection stones: the Stanford experience. Medicine (Baltimore) 1983, 62:44-51.
45. 李瀛輝, 陳明村, 張心湜: 尿路結石. 台北: 九州圖書文物有限公 司; 1980.
46. 孫光煥, 于大雄: 尿路結石之治療最新發展. 台北: 九州圖書文物 有限公司; 1996.
47. 台灣泌尿科醫學會: 尿路結石治療共識準則
http://www.tua.org.tw/administration/index_03.asp. 2008.
48. Burkland CE, Rosenberg M: Survey of urolithiasis in United States. J Urol 1955, 73:198-207.
49. Finlayson B: Symposium on renal lithiasis. Renal lithiasis in review.
Urol Clin North Am 1974, 1:181-212.
50. Wahl C, Hess B: [Kidney calculi--is nutrition a trigger or treatment?].
Ther Umsch 2000, 57:138-145.
51. Rosenfeld L: The chemical work of Alexander and Jane Marcet.
Clinical Chemistry 2001, 47:784-792.
52. Boyce WH: Organic matrix of human urinary concretions. Am J Med 1968, 45:673-683.
53. Boyce WH, King JS, Jr.: Present concepts concerning the origin of matrix and stones. Ann N Y Acad Sci 1963, 104:563-578.
54. Drach GW, Boyce WH: Nephrocalcinosis as a source for renal stone nuclei. Observations on humans and squirrel monkeys and on
hyperparathyroidism in the squirrel monkey. J Urol 1972, 107:897-904.
55. Coe FL, Parks JH, Strauss AL: Acclerated calcium nephrolithiasis.
Jama 1980, 244:809-810.
56. Coe FL, Strauss AL, Tembe V, Le Dun S: Uric acid saturation in calcium nephrolithiasis. Kidney Int 1980, 17:662-668.
57. Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BE:
Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med 1976, 294:249-252.
58. Ito H, Coe FL: Acidic peptide and polyribonucleotide crystal growth inhibitors in human urine. Am J Physiol 1977, 233:F455-463.
59. 陳汶吉: 尿路結石的生物礦化機制探索. 博士論文. 新竹, 臺灣:
國立清華大學; 2001.
60. Khan SR: Interactions between stone-forming calcific crystals and macromolecules. Urol Int 1997, 59:59-71.
61. Menon M, Mahle CJ: Oxalate metabolism and renal calculi. J Urol 1982, 127:148-151.
62. Coe FL, Parks JH: Pathophysiology of kidney stones and strategies for
treatment. Hosp Pract (Off Ed) 1988, 23:185-189, 193-185, 199-200 passim.
63. Nakagawa Y, Ahmed M, Hall SL, Deganello S, Coe FL: Isolation from human calcium oxalate renal stones of nephrocalcin, a
glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. J Clin Invest 1987,
79:1782-1787.
64. Asplin J, DeGanello S, Nakagawa YN, Coe FL: Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 1991, 261:F824-830.
65. Weber DV, Coe FL, Parks JH, Dunn MS, Tembe V: Urinary saturation measurements in calcium nephrolithiasis. Ann Intern Med 1979, 90:180-184.
66. Coe FL, Parks JH, Moore ES: Familial idiopathic hypercalciuria. N Engl J Med 1979, 300:337-340.
67. 歐陽健明, 姚秀琼, 蘇澤軒: 草酸鈣結石的體外模型. 中國科學(B 輯) 2003, 33(1):14-20.
68. Parks JH, Coe FL: A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986, 30:85-90.
69. Parks JH, Coe FL: Urine citrate and calcium in calcium nephrolithiasis. Adv Exp Med Biol 1986, 208:445-449.
70. Robertson WG, Peacock M: The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron 1980, 26:105-110.
71. Senekjian HO, Weinman EJ: Oxalate transport by proximal tubule of the rabbit kidney. Am J Physiol 1982, 243:F271-275.
72. Allison MJ, Cook HM, Milne DB, Gallagher S, Clayman RV: Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 1986, 116:455-460.
73. Danpure CJ: Advances in the enzymology and molecular genetics of primary hyperoxaluria type 1. Prospects for gene therapy. Nephrol Dial Transplant 1995, 10 Suppl 8:24-29.
74. Danpure CJ, Jennings PR: Peroxisomal alanine:glyoxylate
aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 1986, 201:20-24.
75. Williams HE, Johnson GA, Smith LH, Jr.: The renal clearance of oxalate in normal subjects and patients with primary hyperoxaluria.
Clin Sci 1971, 41:213-218.
76. Williams HE, Smith LH, Jr.: Disorders of oxalate metabolism. Am J Med 1968, 45:715-735.
77. Hautmann RE: The stomach: a new and powerful oxalate absorption
in patients with ileal resection: an abnormality in dietary oxalate absorption. Gastroenterology 1974, 66:1114-1122.
79. DeLuca HF: Vitamin D: revisited 1980. Clin Endocrinol Metab 1980, 9:1-26.
80. DeLuca HF: The control of calcium and phosphorus metabolism by the vitamin D endocrine system. Ann N Y Acad Sci 1980, 355:1-17.
81. Meyer JL, Smith LH: Growth of calcium oxalate crystals. II.
Inhibition by natural urinary crystal growth inhibitors. Invest Urol 1975, 13:36-39.
82. Meyer JL, Smith LH: Growth of calcium oxalate crystals. I. A model for urinary stone growth. Invest Urol 1975, 13:31-35.
83. Goldberg H, Grass L, Vogl R, Rapoport A, Oreopoulos DG: Urine citrate and renal stone disease. Cmaj 1989, 141:217-221.
84. Robertson WG, Peacock M: Calcium oxalate crystalluria and
inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 1972, 43:499-506.
85. Asplin J, Parks J, Lingeman J, Kahnoski R, Mardis H, Lacey S,
Goldfarb D, Grasso M, Coe F: Supersaturation and stone composition in a network of dispersed treatment sites. J Urol 1998, 159:1821-1825.
86. Marangella M, Vitale C, Petrarulo M, Bagnis C, Bruno M, Ramello A:
Renal stones: from metabolic to physicochemical abnormalities. How useful are inhibitors? J Nephrol 2000, 13 Suppl 3:S51-60.
87. Ryall RL: Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 1997, 15:155-164.
88. Oldberg A, Franzen A, Heinegard D: Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986, 83:8819-8823.
89. Oldberg A, Ruoslahti E: Evolution of the fibronectin gene. Exon structure of cell attachment domain. J Biol Chem 1986,
261:2113-2116.
90. Moore S, Gowland G: The immunological integrity of matrix
substance A and its possible detection and quantitation in urine. Br J Urol 1975, 47:489-494.
91. Khan SR: Animal model of calcium oxalate nephroilithiasis. In:
Calcium oxalate in biological systems. Edited by Khan SR.
BocaRaton: CRC; 1995.
92. Khan SR, Glenton PA: Deposition of calcium phosphate and calcium oxalate crystals in the kidneys. J Urol 1995, 153:811-817.
93. 鍾玲: 乙二醇法複製腎結石模型給藥途徑和方法的比較. 中國病 理生理雜誌 2000, 16:381-382.
94. 李文峰: 實驗性大鼠腎草酸鈣結石模型的篩選研究. 上海交通大 學學報 2006, 26:66-68.
95. 李瀛輝: 使用乙烯甘醇誘發大白鼠產生尿路結石動物模式之特性.
J Uro ROC 1991, 2:518-524.
96. 李瀛輝: 合併使用 30%高乳糖飲食與 1%乙烯甘醇：一種研究尿路 結石之動物實驗新模式. J Uro ROC 2000, 11:149-154.
97. 王建紅: 豬苓湯抑制腎結石形成的作用機理研究. 湖南中醫藥導 報 2004, 10:80-82.
98. Worcester EM, Chuang M, Laven B, Orvieto M, Coe FL, Evan AP, Gerber GS: A new animal model of hyperoxaluria and nephrolithiasis in rats with small bowel resection. Urol Res 2005, 33:380-382.
99. Connor R, Worcester E, Evan A, S SM, Kuznetsov D, Laven B, Sommer A, SB SB, Parks J, Coe F et al: Nephrolithiasis and
nephrocalcinosis in rats with small bowel resection. Urol Res 2005, 33:105-115.
100. Leth PM, Gregersen M: Ethylene glycol poisoing. Forensic Science International 2005, 155:179-184.
101. Marshall T, Williams KM: Coomassie blue protein dye-binding assays measure formation of an insoluble protein-dye complex. Anal
Biochem 1992, 204:107-109.
102. Marshall T, Williams KM: Bradford protein assay and the transition from an insoluble to a soluble dye complex: effects of sodium dodecyl sulphate and other additives. J Biochem Biophys Methods 1993,
26:237-240.
103. Shevchenko A, Wilm M, Vorm O, Mann M: Mass spectrometric
sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996, 68:850-858.
104. Gharahdaghi F, Weinberg C, Meagher D, Imai B, Missche S: Mass spectrometric identification of proteins from silver-stained
polyacrylamide gel a method for the removal of silver ions to enhance sensitivity. Electrophoresis 1999, 20:601-605.
105. Terry D, Edward U, Desiderio D: Optimized sample-processing time and peptide recovery for the mass spectrometric analysis of protein digests. J Am Soc Mass Spectrom 2004, 15:784-794.
106. Pappin DJ, Hojrup P, Bleasby AJ: Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 1993, 3:327-332.
107. 游士勳, 張錦清: 實用中醫方劑學: 志遠書局; 1989.
108. 南京中醫學院: 中醫方劑學講義. 香港: 醫藥衛生出版社; 1977.
109. 蔡錫英: 桂枝茯苓丸治療石淋及腎積水證 http://www.aptcm.com.
In.; 2001.
110. Yin C, Liu J, Zhang Y: Effects of Alisma orientalis Juzep on calcium oxalate crystallization in vitro and calcium oxalate renal stone in rats.
Acta Univ Med Tongji 1997, 26(2):99-101.
of renal stone formation. . J of Guangzhou University of Traditional Chinese Medicine 2003, 20(4):294-296.
112. Cao ZG, Liu JH, Zhou SW, Wu W, Yin CP, Wu JZ: [The effects of the active constituents of Alisma orientalis on renal stone formation and bikunin expression in rat urolithiasis model]. Zhonghua Yi Xue Za Zhi 2004, 84:1276-1279.
113. Nishijima S, Sugaya K, Morozumi M, Hatano T, Ogawa Y: Hepatic alanine-glyoxylate aminotransferase activity and oxalate metabolism in vitamin B6 deficient rats. J Urol 2003, 169:683-686.
114. Lee IS, Muragaki Y, Ideguchi T, Hase T, Tsuji M, Ooshima A, Okuno E, Kido R: Molecular cloning and sequencing of a cDNA encoding alanine-glyoxylate aminotransferase 2 from rat kidney. J Biochem 1995, 117:856-862.
115. Grover PK, Dogra SC, Davidson BP, Stapleton AM, Ryall RL: The prothrombin gene is expressed in the rat kidney: Implications for urolithiasis research. Eur J Biochem 2000, 267:61-67.
116. Kumar V, Farell G, Yu S, Harrington S, Fitzpatrick L, Rzewuska E, Miller VM, Lieske JC: Cell biology of pathologic renal calcification:
contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J Investig Med 2006, 54:412-424.
117. Coulter-Mackie MB, White CT, Hurley RM: Primary Hyperoxaluria Type
1 :http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=p h1. 2006.
118. http://www.ghr.nlm.nih.gov/condition=primaryhyperoxaluria 119. Coulter-Mackie MB: Preliminary evidence for ethnic differences in
primary hyperoxaluria type 1 genotype. Am J Nephrol 2005, 25:264-268.
120. Koul S, Johnson T, Pramanik S, Koul H: Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1). Am J Nephrol 2005, 25:176-182.
121. Leiper JM, Danpure CJ: A unique molecular basis for enzyme
mistargeting in primary hyperoxaluria type 1. Clin Chim Acta 1997, 266:39-50.
122. Leiper JM, Oatey PB, Danpure CJ: Inhibition of alanine:glyoxylate aminotransferase 1 dimerization is a prerequisite for its
peroxisome-to-mitochondrion mistargeting in primary hyperoxaluria type 1. J Cell Biol 1996, 135:939-951.
123. Danpure CJ: Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am J Nephrol 2005, 25:303-310.
124. Danpure CJ: Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant 2005, 20:1525-1529.
125. Green M, Hatch M, Freel R: Ethylene glycol induces hyperoxaluria without metabolic acidosis in rats. AM J Physiol Renal Physiol 2005, 289:F536-F543.
126. Lee Y, Tsai J, Huang J: Combined use of 30% lactose rich diet and 1%
ethylene glycol: a new animal model for study of urolithiasis. J Urol ROC 2000, 11:149-154.
127. Tsai CH, Chen YC, Chen LD, Pan TC, Ho CY, Lai MT, Tsai FJ, Chen WC: A traditional Chinese herbal antilithic formula, Wulingsan,
127. Tsai CH, Chen YC, Chen LD, Pan TC, Ho CY, Lai MT, Tsai FJ, Chen WC: A traditional Chinese herbal antilithic formula, Wulingsan,